Novartis’s Inclisiran Unscathed As Arrowhead Falls Short
But NASH Candidate Generates Interest
Arrowhead’s drug has failed to match inclisiran’s performance, but its RNAi platform has other promising candidates.
Arrowhead’s drug has failed to match inclisiran’s performance, but its RNAi platform has other promising candidates.